SGMT · Categories · Form 4

SGMT - SEC Form 4 insider transactions

Sagimet Biosciences Inc. (SGMT) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for SGMT

• 12d
  SEC Form 4 filed by Chief Financial Officer Chauche Thierry

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 12d
  SEC Form 4 filed by Chief Medical Officer Grauer Andreas

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 12d
  SEC Form 4 filed by Chief Legal & Admin. Officer Rozek Elizabeth

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 12d
  SEC Form 4 filed by President & CEO Happel David

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 30d
  SEC Form 4 filed by Chief Medical Officer Grauer Andreas

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 113d
  Chief Legal & Admin. Officer Rozek Elizabeth was granted 44,000 units of Series A Common Stock, increasing direct ownership by 23% to 234,959 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 113d
  Chief Medical Officer Martins Eduardo Bruno was granted 44,000 units of Series A Common Stock, increasing direct ownership by 43% to 147,296 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 113d
  President & CEO Happel David was granted 128,000 units of Series A Common Stock, increasing direct ownership by 19% to 805,621 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 113d
  Chief Financial Officer Chauche Thierry was granted 44,000 units of Series A Common Stock, increasing direct ownership by 280% to 59,688 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 121d
  President & CEO Happel David sold $64,865 worth of Series A Common Stock (12,101 units at $5.36), decreasing direct ownership by 2% to 677,621 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 121d
  Chief Financial Officer Chauche Thierry sold $7,033 worth of Series A Common Stock (1,312 units at $5.36), decreasing direct ownership by 8% to 15,688 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 121d
  Chief Medical Officer Martins Eduardo Bruno sold $19,511 worth of Series A Common Stock (3,640 units at $5.36), decreasing direct ownership by 3% to 103,296 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 121d
  Chief Legal & Admin. Officer Rozek Elizabeth sold $14,054 worth of Series A Common Stock (2,622 units at $5.36), decreasing direct ownership by 1% to 190,959 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 204d
  Executive Chairman Kemble George sold $289,979 worth of Series A Common Stock (37,688 units at $7.69), decreasing direct ownership by 32% to 81,005 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 219d
  Chief Legal & Admin. Officer Rozek Elizabeth was granted 9,855 units of Series A Common Stock, increasing direct ownership by 5% to 193,581 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 325d
  President & CEO Happel David sold $598,115 worth of Series A Common Stock (65,478 units at $9.13), decreasing direct ownership by 9% to 689,722 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 325d
  Chief Medical Officer Martins Eduardo Bruno sold $75,607 worth of Series A Common Stock (8,277 units at $9.13), decreasing direct ownership by 7% to 106,936 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 325d
  General Counsel and CCO Rozek Elizabeth sold $98,471 worth of Series A Common Stock (10,780 units at $9.13), decreasing direct ownership by 6% to 183,726 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Seidenberg Beth C

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Phillips Anne M.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Kemble George

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Jarrett Jennifer

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 368d
  SEC Form 4 filed by Director Grammer Elizabeth A

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 491d
  Chief Medical Officer Martins Eduardo Bruno was granted 34,000 units of Series A Common Stock, increasing direct ownership by 42% to 115,213 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 491d
  President & CEO Happel David was granted 116,000 units of Series A Common Stock, increasing direct ownership by 18% to 755,200 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 491d
  General Counsel and CCO Rozek Elizabeth was granted 34,000 units of Series A Common Stock, increasing direct ownership by 21% to 194,506 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 491d
  Chief Financial Officer Chauche Thierry was granted 17,000 units of Series A Common Stock (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 677d
  SEC Form 4 filed by Director Jarrett Jennifer

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 677d
  SEC Form 4 filed by Director Phillips Anne M.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 688d
  Executive Chairman Kemble George sold $74,830 worth of Series A Common Stock (23,625 units at $3.17), decreasing direct ownership by 17% to 118,693 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 690d
  Chief Medical Officer Martins Eduardo Bruno sold $25,910 worth of Series A Common Stock (8,357 units at $3.10), decreasing direct ownership by 9% to 81,213 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 690d
  General Counsel and CCO Rozek Elizabeth sold $33,830 worth of Series A Common Stock (10,914 units at $3.10), decreasing direct ownership by 6% to 160,506 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 690d
  Executive Chairman Kemble George sold $43,605 worth of Series A Common Stock (14,062 units at $3.10), decreasing direct ownership by 9% to 142,318 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 736d
  SEC Form 4 filed by Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 736d
  SEC Form 4 filed by Seidenberg Beth C

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 736d
  SEC Form 4 filed by Parsey Merdad

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 736d
  SEC Form 4 filed by Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 736d
  SEC Form 4 filed by Grammer Elizabeth A

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 766d
  SEC Form 4 filed by Chauche Thierry

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 801d
  SEC Form 4 filed by Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 801d
  SEC Form 4 filed by Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

Other SGMT categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends